|
Short facts |
|
|
Technology |
GAIA´s proprietary artificial intelligence (AI)-expert system, broca® |
|
Indication |
Opioid use disorder (OUD) |
|
Period of use |
6 months |
|
Commercial rights |
Orexo owns the global rights |
|
Partner |
Developed together with |
|
Launch |
US launch expected to be initiated in H2 2021 |
|
Key advantages |
|
|
Pivotal study |
Large pivotal study initiated in June 2021 where the efficacy of modia™ is evaluated along with bup/nal pharma treatment |
Unmet need
The medically assisted treatment of opioid use disorder requires a complete treatment plan, including effective pharmaceutical treatment, such as Orexo’s commercially available ZUBSOLV®, along with counseling or psychosocial support. The access and quality of counseling and psychosocial support remain one of the main barriers to successful treatment in many areas of the US. Orexo believes that the fully-automated digital therapy can become a valuable addition to existing treatment plans, which will improve patients’ access to treatment and overall treatment outcomes.
About the Pivotal modia™ Study
Large pivotal study initiated in June 2021, where the efficacy of modia™ is evaluated along with bup/nal pharma treatment.
Related links
About GAIA
The press release communicating the partnership
https://orexo.com/en/media/press-releases?releaseId=B4A65108A4D7F345
Press release regarding the first patient in modia's pivotal study
https://mb.cision.com/Main/694/3377614/1439218.pdf